CNTB

0.59006.08%
BD

Barry David Quart

CEO & Director

Dr. Barry David Quart, Pharm.D., serves as Chief Executive Officer & Director of Connect Biopharma Holdings Limited since June 12, 2024. He had served as Chief Executive Officer of Heron Therapeutics, Inc. since May 2013 until May 2023 and had been its Director since 2013 until April 3, 2023. Dr. Quart had served as Chairman of Heron Therapeutics, Inc. since October 13, 2020 until April 3, 2023. He also served as President at Heron Therapeutics, Inc. from February 2019 until October 13, 2020. Dr. Quart serves as the Scientific Advisor of Napo Pharmaceuticals, Inc. Dr. Quart has experience serving in leadership positions in biotechnology and pharmaceutical companies and developing innovative pharmaceutical products. Dr. Quart was Principal Financial Officer and Principal accounting officer at Heron Therapeutics since April 1, 2017 until April 24, 2017. He served as the Chief Executive Officer and President at Ardea Biosciences, Inc. since December 21, 2006 until May 2013, which he co founded in 2006. He served as the President of Napo Pharmaceuticals Inc. from June 2002 to July 31, 2006 and served as its Chief Scientific Officer until July 31, 2006. He served as the President and Chief Executive Officer of Intrabiotics Pharmaceuticals Inc. since December 22, 2006. He served as Senior Vice President of Pfizer Global Research and Development. He served as Senior Vice President and Head of Drug Development for Agouron Pharmaceuticals Inc., a division of the Warner Lambert Company, since 1997 and also served as its President of Research and Development. since 1999, where he was instrumental in the development and registration of Viracept, which went from the lab bench to NDA approval in 38 months. Dr. Quart served as Vice President of Regulatory Affairs for Agouron Pharmaceuticals Inc. since joining it in 1993. He served as an Executive Director of international regulatory affairs for Bristol Myers Squibb Company since 1992. Dr. Quart served with Bristol Myers Squibb for experience in both Clinical Research and Regulatory Affairs, where he was actively involved in the development and registration of nine important drugs, including paclitaxel, didanosine, stavudine and sotalol. Within the newly created Pfizer Global Research and Development Division, he served as Senior Vice President of La Jolla Laboratories. He serves as a Director of NeuroGenetic Pharmaceuticals, Inc. He serves as an Independent Director at Kiniksa Pharmaceuticals International, plc (formerly known as Kiniksa Pharmaceuticals, Ltd.) since October 2015. He was a Director of Ardea Biosciences, Inc. since December 21, 2006 until 2012. Dr. Quart served as a Director of Trimeris Inc. since June 2007 and Synageva BioPharma Corp. from June 2007 to June 22, 2015. He served as a Director of Napo Pharmaceuticals Inc. from May 2, 2002 to July 7, 2006. He served as an Executive Director of Intrabiotics Pharmaceuticals Inc. since December 22, 2006. He served as a Director of the La Jolla Laboratories. Dr. Quart received a Pharm.D. in clinical pharmacy from the University of California, San Francisco.

Positions